Intra-tumoral N17350 administration induces rapid, genotype-independent tumor regression, triggering CD8<sup>+</sup> T cell activation to promote durable responses and enable checkpoint inhibitor efficacy in refractory models. This evidence concerns the gene CD8A and neoplasm.